Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSI NASDAQ:NKTR NASDAQ:PCRX NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsNKTRNektar Therapeutics$22.96+5.9%$18.44$6.45▼$37.38$268.98M0.95911,784 shs504,568 shsPCRXPacira BioSciences$22.07+4.6%$23.83$11.16▼$27.64$976.27M0.48530,650 shs1.21 million shsSUPNSupernus Pharmaceuticals$35.51+1.2%$32.64$27.05▼$40.28$1.97B0.74755,351 shs858,699 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics+5.90%-8.16%-10.07%+103.55%+14.23%PCRXPacira BioSciences+4.65%-2.13%-4.91%-16.56%+6.88%SUPNSupernus Pharmaceuticals+1.17%+5.75%+10.73%+8.13%+19.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/AN/AN/AN/ANKTRNektar Therapeutics4.236 of 5 stars3.43.00.04.23.82.50.0PCRXPacira BioSciences3.5321 of 5 stars2.22.00.03.93.42.50.6SUPNSupernus Pharmaceuticals1.949 of 5 stars1.31.00.04.13.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSIBioDelivery Sciences International 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.33284.73% UpsidePCRXPacira BioSciences 2.44Hold$25.7516.67% UpsideSUPNSupernus Pharmaceuticals 2.67Moderate Buy$39.009.83% UpsideCurrent Analyst Ratings BreakdownLatest BDSI, SUPN, PCRX, and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$42.007/25/2025PCRXPacira BioSciencesTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$30.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $85.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.005/12/2025NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform5/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSIBioDelivery Sciences International$166.70M3.46$0.36 per share15.42$1.90 per share2.94NKTRNektar Therapeutics$98.43M2.89N/AN/A$4.94 per share4.65PCRXPacira BioSciences$700.97M1.46$4.51 per share4.89$16.86 per share1.31SUPNSupernus Pharmaceuticals$661.82M3.00$4.22 per share8.42$18.76 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSIBioDelivery Sciences International$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/ANKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/7/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A8.59N/A-14.78%13.78%7.00%8/5/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1131.9924.66N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest BDSI, SUPN, PCRX, and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NKTRNektar Therapeutics-$2.58N/AN/AN/A$9.42 millionN/A8/5/2025Q2 2025PCRXPacira BioSciences$0.73N/AN/AN/A$183.11 millionN/A8/5/2025Q2 2025SUPNSupernus Pharmaceuticals$0.47N/AN/AN/A$154.06 millionN/A5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSIBioDelivery Sciences International0.292.452.17NKTRNektar TherapeuticsN/A3.243.24PCRXPacira BioSciences0.482.411.99SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSIBioDelivery Sciences International64.40%NKTRNektar Therapeutics75.88%PCRXPacira BioSciences99.73%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBDSIBioDelivery Sciences International9.98%NKTRNektar Therapeutics5.25%PCRXPacira BioSciences6.40%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSIBioDelivery Sciences International200103.23 million92.93 millionOptionableNKTRNektar Therapeutics22012.41 million11.76 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableBDSI, SUPN, PCRX, and NKTR HeadlinesRecent News About These CompaniesSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Cantor FitzgeraldAugust 1 at 2:16 AM | americanbankingnews.comSupernus Pharmaceuticals Completes Acquisition of Sage TherapeuticsJuly 31 at 9:16 AM | tipranks.comSupernus Pharmaceuticals Completes Acquisition of Sage TherapeuticsJuly 31 at 8:44 AM | globenewswire.comSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Cantor Fitzgerald to "Overweight" RatingJuly 31 at 7:33 AM | marketbeat.com65,585 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Universal Beteiligungs und Servicegesellschaft mbHJuly 31 at 3:25 AM | marketbeat.comHead to Head Analysis: Supernus Pharmaceuticals (NASDAQ:SUPN) versus Acura Pharmaceuticals (OTCMKTS:ACUR)July 31 at 2:37 AM | americanbankingnews.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Could Be 50% Below Their Intrinsic Value EstimateJuly 30 at 10:59 PM | finance.yahoo.comWhy Supernus Pharmaceuticals (SUPN) Stock Is Up TodayJuly 30 at 10:59 PM | msn.comSupernus Pharmaceuticals (SUPN) Projected to Post Quarterly Earnings on TuesdayJuly 30 at 8:25 AM | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by GSA Capital Partners LLPJuly 29, 2025 | marketbeat.comRoyce & Associates LP Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 29, 2025 | marketbeat.comSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender OfferJuly 28, 2025 | globenewswire.comPacer Advisors Inc. Has $13.22 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 27, 2025 | marketbeat.comBranded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)July 25, 2025 | msn.comBurney Co. Lowers Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 24, 2025 | marketbeat.comSupernus Pharmaceuticals Inc (SUPN) Announces Upcoming Q2 2025 Financial Results Release | SUPN ...July 22, 2025 | gurufocus.comSupernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025July 22, 2025 | globenewswire.comVictory Capital Management Inc. Has $22.03 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 22, 2025 | marketbeat.comGW&K Investment Management LLC Buys 176,091 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 21, 2025 | marketbeat.comBank of New York Mellon Corp Reduces Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 21, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street ZenJuly 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDSI, SUPN, PCRX, and NKTR Company DescriptionsBioDelivery Sciences International NASDAQ:BDSIBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Nektar Therapeutics NASDAQ:NKTR$22.96 +1.28 (+5.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.32 +0.36 (+1.55%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Pacira BioSciences NASDAQ:PCRX$22.07 +0.98 (+4.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.07 0.00 (0.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Supernus Pharmaceuticals NASDAQ:SUPN$35.51 +0.41 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$35.52 +0.01 (+0.01%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
